A Phase 3 interventional study of Ponesimod in Multiple Sclerosis, sponsored by Actelion. Completed at 148 sites in 28 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-22.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Multiple Sclerosis with a site in Russian Federation — none open to participants now, none under way, none of them phase 3. Multiple Sclerosis · Russian Federation.
Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, this one is the 21st largest by enrollment of the 83 interventional ones that give a count, is one of 3 that started in 2017, is one of 40 in phase 3, and was the 73rd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →None of the 86 studies in Multiple Sclerosis with a site in Russian Federation is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 34 · Phase 3 42 · Phase 4 5
First in 2002; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 877 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 402 across the 83 interventional studies, 307 across the 3 observational. Of the 82 that completed or were terminated, 65 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 86 have an industry lead sponsor. The 10 most frequent:
This study is registered under Actelion, one of the names counted as Johnson & Johnson. Under that name alone:
Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
Johnson & Johnson has 7 studies filed under Multiple Sclerosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 86 studies in Multiple Sclerosis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS). The AC-058B303 study is the long-term extension for the core study AC-058B301. The purpose of this long term extension of the core study AC-058B301 is to characterize the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with RMS.
The AC-058B303 study (extension study) is the long-term extension for the AC-058B301 study (core study). The core study has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with RMS. The subjects are treated with either ponesimod or the active comparator, teriflunomide in the core study. The purpose of this long term extension of the core study is to characterize the long-term safety and control of disease of ponesimod in subjects with RMS. In particular, the study will allow to observe potential adverse events which may only occur after long term treatment with ponesimod. The study will also investigate the effect of re-initiation of ponesimod after a brief interruption in a relatively large population (all subjects treated with ponesimod in the core study and eligible for the extension study) on disease activity in terms of relapses and MS-related MRI lesions. There is currently limited guidance on when a new MS treatment should be started after discontinuation of teriflunomide and the study will contribute with data on safety and efficacy of switching from teriflunomide to ponesimod after an interruption as mandated by the protocol. The study will also allow confirmation of sustained efficacy of ponesimod in terms of relapses, MRI lesions and reduction of disability accumulation during long-term treatment. In addition, combined data from the core study together with the results of the current extension study will allow comparison of MS activity in subjects who were switched from teriflunomide to ponesimod versus those who were treated with ponesimod in both studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any of the following cardiovascular conditions on Day 1 pre-dose:
Any of the following alerts from central laboratory at Visit 14 of the core study (EOT) which was confirmed as an alert at repeated testing or not repeated prior to FU1 of the core study:
Presence of the following at core study Visit 14 (EOT, Week 108), FU1, or abbreviated visit FU2, or on Day 1 of the extension study pre-dose:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mg administered orally once daily
Drug: Ponesimod
Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
Annualized Confirmed Relapse Rate (ARR)
ARR: number of confirmed relapses per patient-year. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours, in the absence of fever or infection. A confirmed relapse is identified when a patient's symptoms worsen as indicated by an increase in their Expanded Disability Status Scale (EDSS) or Functional Systems (FS) scores, consistent with previous clinically stable assessments. Specific criteria for a confirmed relapse include: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0 (normal)-10 (death due to MS).
Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Time From Core Study Randomization to First Confirmed Relapse
Time to first confirmed relapse: date of first confirmed relapse (in either core or extension study) minus date of randomization in core study+1 day. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse are: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS).
Time frame: From randomization in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Time to First 12-week Confirmed Disability Accumulation (CDA)
Time to first 12-week CDA is defined as start date of the first 12-week CDA minus date of randomization in the core study + 1 day. A 12-week CDA is defined as a 12-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 12-weeks. CDA is defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 12 weeks. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Time to First 24-week Confirmed Disability Accumulation (CDA)
Time to first 24-week CDA was defined as start date of the first 24-week CDA minus date of randomization in the core study + 1 day. A 24-week CDA was defined as a 24-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 24-weeks. CDA was defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 24 weeks. EDSS was an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Percentage of Participants With Absence of Relapses
Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Change From Baseline in Expanded Disability Status Scale (EDSS)
EDSS is ordinal clinical rating scale based on standard neurological examination for assessing neurological disability and impairment in MS. Seven FS scores were rated on a scale ranged from 0 to 5 or 6 to assess visual, brain, stem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral functions while ambulation was scored on scale ranged from 0 to 12 to assess walking distance and assistance. Individual FS scores were then used in conjugation with ambulation score to obtain EDSS score which ranged from 0 (normal) to 10 (death due to MS) in 0.5 unit increments that represented higher levels of disability. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study
NEDA-3 up to extension EOS is defined by the absence of confirmed relapse, gadolinium-enhancing (Gd+ T1) lesions, new or enlarging T2 lesions, and 12-week CDA. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-3. Confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study
NEDA-4 up to EOS is defined by the absence of confirmed relapse, Gd+ T1 lesions, new or enlarging T2 lesions, 12-week CDA until EOS, and absence of annual brain volume decrease \>=0.4% from core baseline up to extension EOS. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-4. Confirmed relapse: when patient's symptoms worsen by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in core study for each outcome measure and each participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI)
Percent change from baseline in brain volume (PCBV) measured by MRI were reported. Normalized Brain Volume at core baseline was measured in cubic centimeter (cm\^3). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI
CUALs was calculated as sum of new T1 Gadolinium-enhanced (Gd+) lesions and new or enlarging T2 lesions (without double-counting of lesions) from baseline up to extension EOS based on the Magnetic resonance imaging (MRI). Average number of lesions per patient-year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI
Number of Gd+ T1 lesions measured by MRI were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. For this outcome measure, results presented here are for the Extension end-of-treatment visit.
Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Cumulative Number of New or Enlarging T2 Lesions Measured by MRI
Cumulative number of new or enlarging T2 lesions measured by MRI were reported. Average number of lesions per year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
Time frame: From baseline in the core study up to the end of study (EOS) in the extension study. The actual time varied for each participant and could be up to 98.5 months
Change From Baseline in Volume of MRI Lesions (T2 Lesions and T1 Hypointense Lesions)
Change from baseline in volume of MRI lesions (T2 lesions, T1 hypointense lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Number of Participants With Absence of MRI Lesions (Gd+ T1 Lesions, New or Enlarging T2 Lesions)
Number of participants with absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs)
Percentage of Gd+ lesions at baseline evolving to PBHs were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From baseline in the core study up to the end of treatment (EOT) in the extension study. The actual time varied for each participant and could be up to 94.8 months
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of participants with TEAEs were reported. An AE is any untoward medical event that occurs in a participants being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities
Number of participants with treatment-emergent new morphological ECG abnormalities were reported. Treatment-emergent new morphological ECG abnormalities are defined as those ECG abnormalities occurring from start of treatment up to treatment end date + 15 days.
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate
Actual values of 12-lead ECG measurements up to end of study treatment: heart rate were reported. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Actual Values of 12-lead ECG Measurements up to End of Study Treatment: PR, QRS, QT, QTcB, QTcF
Actual values of 12-lead ECG measurements up to end of study treatment: PR, QRS, QT, QTcB, QTcF were reported. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Change in Heart Rate (HR) From Baseline up to End of Study Treatment
Change in heart rate (HR) from baseline up to end of study treatment were reported.
Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Change in PR, QRS, QT, QTcB, QTcF From Baseline up to End of Study Treatment
Change in PR, QRS, QT, QTcB, QTcF from baseline up to end of study treatment were reported.
Time frame: From the start of study treatment in the extension study up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Absolute Values in Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) Values
Absolute values in FEV1 and FVC values were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. Results are presented for extension end of treatment visit.
Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Percent Change in (FEV1) and Forced Vital Capacity (FVC) From Baseline (%)
Percent change in FEV1 and FVC from baseline (%) were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. In this outcome measure, results were presented for extension end of treatment visit.
Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs)
Number of participants with treatment-emergent SAEs were reported. A SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. Treatment-emergent SAEs are defined as SAEs occurring from start of treatment up to treatment end date + 15 days.
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With Treatment-emergent Adverse Events of Special Interest (AESIs)
Number of participants with treatment-emergent AESIs were reported. AESIs included bradyarrhythmia occurred post-first dose, macular edema, bronchoconstriction, severe liver injury, serious opportunistic infections including progressive multifocal leukoencephalopathy (PML), skin cancer, non-skin malignancy, convulsions, unexpected neurological or psychiatric symptoms/signs (posterior reversible encephalopathy syndrome \[PRES\], acute disseminated encephalomyelitis \[ADEM\], and atypical MS relapses). Treatment-emergent AESIs are defined as AESIs occurring from start of treatment up to treatment end date + 15 days.
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With AE Leading to Premature Discontinuation of Study Treatment
Number of participants with AE leading to premature discontinuation of study treatment were reported. An AE is any untoward medical event that occurs in a participant being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With Treatment-emergent Decrease From Baseline >20% and >30% in FEV1 or FVC
Number of participants with treatment-emergent decrease from baseline \>20% and \>30% in FEV1 or FVC were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With Treatment-emergent Decrease of >20% Points in Percent Predicted FEV1 and FVC From Baseline
Number of participants with treatment-emergent decrease of \>20% points in percent predicted FEV1 and FVC from baseline were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).
Time frame: From the start of study treatment in the extension study up to the end of study treatment + 15 days in the extension study. The actual time varied for each participant and could be up to 71.8 months + 15 days
Number of Participants With a Decrease of >=200 mL or >=12% in FEV1 or FVC From Baseline to EOT
Number of participants with a decrease of \>=200 mL or \>=12% in FEV1 or FVC from baseline to EOT were planned to be reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. This endpoint is not relevant as a substantial proportion of patients continued onto post-treatment disease-modifying therapy (DMT), hence it cannot provide an assessment of reversibility.
Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Change in FEV1 and FVC (% Predicted) From Baseline to End of Treatment (EOT)
Change in FEV1 and FVC (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Change in FEV1 and FVC (% Predicted) From Baseline to End of Study (EOS)
Change in FEV1 and FVC (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline
Absolute change in lung diffusion capacity as assessed by DL\[CO\] from baseline were reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Change in DL[CO] (% Predicted) From Baseline to EOT
Change in DL\[CO\] (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
Time frame: From extension study baseline up to the end of study treatment in the extension study. The actual time varied for each participant and could be up to 71.8 months
Change in DL[CO] (% Predicted) From Baseline to EOS
Change in DL\[CO\] (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
Time frame: From extension study baseline up to the end of study in the extension study. The actual time varied for each participant and could be up to 73.2 months
Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: Heart Rate
Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: heart rate were reported.
Time frame: Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])
Actual Values of 12-lead ECG Measurements on Day of First Re-initiation (Day 1) of Study Drug: PR, QRS, QT, QTcB, QTcF
Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: PR, QRS, QT, QTcB, QTcF were reported.
Time frame: Extension analysis period: Predose, 1, 2, 3, 4 hours post dose on Day 1 of re-initiation (re-initiation could occur on any day during the treatment period when drug was interrupted for at least 3 consecutive days [up to 71.8 months])
Total of 877 participants entered this extension study from the core study (NCT02425644) and all received at least one dose of ponesimod 20 milligrams (mg) treatment.
| Milestone | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Started | 439 | 438 |
| Completed | 352 | 371 |
| Not completed | 87 | 67 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Adverse event | 7 | 12 |
| Withdrew: Lost to follow-up | 6 | 6 |
| Withdrew: Lack of efficacy | 10 | 8 |
| Withdrew: Physician decision | 9 | 2 |
| Withdrew: Withdrawal by subject | 54 | 39 |
ARR: number of confirmed relapses per patient-year. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours, in the absence of fever or infection. A confirmed relapse is identified when a patient's symptoms worsen as indicated by an increase in their Expanded Disability Status Scale (EDSS) or Functional Systems (FS) scores, consistent with previous clinically stable assessments. Specific criteria for a confirmed relapse include: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0 (normal)-10 (death due to MS).
| relapses per patient-year | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Annualized Confirmed Relapse Rate (ARR) | 0.143 (0.123 to 0.167) | 0.184 (0.158 to 0.213) |
Time to first confirmed relapse: date of first confirmed relapse (in either core or extension study) minus date of randomization in core study+1 day. Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse are: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS).
| Weeks | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Time From Core Study Randomization to First Confirmed Relapse | 402.71 (82.29 to NA) | NA (53.57 to NA) |
Time to first 12-week CDA is defined as start date of the first 12-week CDA minus date of randomization in the core study + 1 day. A 12-week CDA is defined as a 12-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 12-weeks. CDA is defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 12 weeks. EDSS is an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
| Weeks | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Time to First 12-week Confirmed Disability Accumulation (CDA) | NA (NA to NA) | NA (254.86 to NA) |
Time to first 24-week CDA was defined as start date of the first 24-week CDA minus date of randomization in the core study + 1 day. A 24-week CDA was defined as a 24-week sustained increase from the core baseline EDSS score, which is confirmed at a scheduled visit after 24-weeks. CDA was defined as: (a) Sustained increase of at least 1.5 in EDSS for participants with a core baseline EDSS score of 0; (b) Sustained increase of at least 1.0 in EDSS for participants with a core baseline EDSS score of 1.0 to 5.0; (c) Sustained increase of at least 0.5 in EDSS for participants with a core baseline EDSS score \>=5.5, confirmed after 24 weeks. EDSS was an ordinal clinical rating scale ranging from 0 (normal neurological examination) to 10 (death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
| Weeks | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Time to First 24-week Confirmed Disability Accumulation (CDA) | NA (NA to NA) | NA (313.29 to NA) |
Relapse: new, worsening, or recurrent neurological symptoms that occurred at least 30 days after the onset of a preceding relapse, and that lasted at least 24 hours in absence of fever or infection. A confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Specific criteria for confirmed relapse: An increase of 0.5 points on EDSS; (unless EDSS=0, then requires an increase of 1.0-point); An increase of at least 1.0 point in at least two FS scores; or a 2.0-point increase in one FS score (excluding bladder/bowel and cerebral). Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging:0(normal)-10(death due to MS). Core baseline for efficacy: last non-missing value recorded before or on randomization in the core study for each outcome measure and participant individually.
| Percentage of Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Percentage of Participants With Absence of Relapses | 56.7 | 51.6 |
EDSS is ordinal clinical rating scale based on standard neurological examination for assessing neurological disability and impairment in MS. Seven FS scores were rated on a scale ranged from 0 to 5 or 6 to assess visual, brain, stem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral functions while ambulation was scored on scale ranged from 0 to 12 to assess walking distance and assistance. Individual FS scores were then used in conjugation with ambulation score to obtain EDSS score which ranged from 0 (normal) to 10 (death due to MS) in 0.5 unit increments that represented higher levels of disability. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
| Score on a scale | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Change From Baseline in Expanded Disability Status Scale (EDSS) | 0.16 ± 1.008 | 0.34 ± 1.105 |
NEDA-3 up to extension EOS is defined by the absence of confirmed relapse, gadolinium-enhancing (Gd+ T1) lesions, new or enlarging T2 lesions, and 12-week CDA. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-3. Confirmed relapse: when patient's symptoms worsen as indicated by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
| Percentage of Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Three Components (NEDA-3) at Extension End of Study | 17.5 | 7.5 |
NEDA-4 up to EOS is defined by the absence of confirmed relapse, Gd+ T1 lesions, new or enlarging T2 lesions, 12-week CDA until EOS, and absence of annual brain volume decrease \>=0.4% from core baseline up to extension EOS. If at least one of the criteria was not fulfilled or the participant discontinued treatment prematurely, the participant was not considered to have achieved NEDA-4. Confirmed relapse: when patient's symptoms worsen by an increase in their EDSS/FS scores, consistent with previous clinically stable assessments. Rating individual FS scores is used to rate EDSS along with observations and information concerning gait and use of assistance. EDSS is ordinal clinical rating scale ranging: 0 (normal)-10 (death due to MS). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in core study for each outcome measure and each participant individually.
| Percentage of Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Percentage of Participants With No Evidence of Disease Activity (NEDA) Status According to NEDA With Four Components (NEDA-4) at Extension End of Study | 5.2 | 2.3 |
Percent change from baseline in brain volume (PCBV) measured by MRI were reported. Normalized Brain Volume at core baseline was measured in cubic centimeter (cm\^3). Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
| Percent Change | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Percent Change From Baseline in Brain Volume (PCBV) Measured by Magnetic Resonance Imaging (MRI) | -2.52 ± 2.179 | -2.72 ± 2.024 |
CUALs was calculated as sum of new T1 Gadolinium-enhanced (Gd+) lesions and new or enlarging T2 lesions (without double-counting of lesions) from baseline up to extension EOS based on the Magnetic resonance imaging (MRI). Average number of lesions per patient-year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
| CUAL per patient-year | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Cumulative Number of Combined Unique Active Lesions (CUAL) Measured by MRI | 1.352 (1.153 to 1.586) | 1.954 (1.667 to 2.291) |
Number of Gd+ T1 lesions measured by MRI were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. For this outcome measure, results presented here are for the Extension end-of-treatment visit.
| Gd+ T1 lesions | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Number of Gadolinium-enhancing (Gd+) T1 Lesions Measured by MRI | 0.211 (0.131 to 0.341) | 0.395 (0.250 to 0.622) |
Cumulative number of new or enlarging T2 lesions measured by MRI were reported. Average number of lesions per year were reported. Results are based on a negative-binomial regression model. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually.
| Lesions per year | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Cumulative Number of New or Enlarging T2 Lesions Measured by MRI | 1.352 (1.152 to 1.586) | 1.951 (1.664 to 2.287) |
Change from baseline in volume of MRI lesions (T2 lesions, T1 hypointense lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
| cubic millimeters (mm^3) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| T2 Lesions | -435.7 ± 2822.71 | 91.5 ± 3647.08 |
| T1 Hypointense Lesions | 165.6 ± 1427.30 | 309.4 ± 1712.36 |
Number of participants with absence of MRI lesions (Gd+ T1 lesions, new or enlarging T2 lesions) were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Gd+ T1 lesions | 293 | 236 |
| T2 lesions | 152 | 101 |
Percentage of Gd+ lesions at baseline evolving to PBHs were reported. Core baseline for efficacy is defined as the last non-missing value recorded before or on randomization in the core study for each outcome measure and each participant individually. In this outcome measure, results were presented for extension end of treatment visit.
| Percentage of lesions | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Percentage of Gd+ Lesions at Baseline Evolving to Persistent Black Holes (PBHs) | 22.3 | 25.1 |
Number of participants with TEAEs were reported. An AE is any untoward medical event that occurs in a participants being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 411 | 410 |
Number of participants with treatment-emergent new morphological ECG abnormalities were reported. Treatment-emergent new morphological ECG abnormalities are defined as those ECG abnormalities occurring from start of treatment up to treatment end date + 15 days.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Number of Participants With Treatment-emergent New Morphological Electrocardiogram (ECG) Abnormalities | 153 | 140 |
Actual values of 12-lead ECG measurements up to end of study treatment: heart rate were reported. In this outcome measure, results were presented for extension end of treatment visit.
| Beats per minute (bpm) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Actual Values of 12-lead ECG Measurements up to End of Study Treatment: Heart Rate | 67.4 ± 9.64 | 67.6 ± 9.33 |
Actual values of 12-lead ECG measurements up to end of study treatment: PR, QRS, QT, QTcB, QTcF were reported. In this outcome measure, results were presented for extension end of treatment visit.
| millisecond (ms) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| PR Interval | 150.0 ± 20.41 | 153.3 ± 20.27 |
| QRS Duration | 92.1 ± 9.22 | 93.3 ± 10.63 |
| QT Interval | 392.5 ± 27.26 | 391.0 ± 25.67 |
| QTcB Interval | 414.8 ± 19.20 | 413.8 ± 19.66 |
| QTcF Interval | 406.9 ± 17.78 | 405.7 ± 17.78 |
Change in heart rate (HR) from baseline up to end of study treatment were reported.
| beats per minute (bpm) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Change in Heart Rate (HR) From Baseline up to End of Study Treatment | -1.7 ± 10.00 | -1.5 ± 9.17 |
Change in PR, QRS, QT, QTcB, QTcF from baseline up to end of study treatment were reported.
| millisecond (ms) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| PR Interval | 0.5 ± 14.09 | 2.0 ± 14.37 |
| QRS Duration | -0.4 ± 6.79 | 2.9 ± 6.88 |
| QT Interval | 7.8 ± 25.68 | 8.9 ± 21.66 |
| QTcB Interval | 2.9 ± 16.75 | 5.2 ± 17.07 |
| QTcF Interval | 4.6 ± 15.28 | 6.5 ± 14.18 |
Absolute values in FEV1 and FVC values were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. Results are presented for extension end of treatment visit.
| Liters (L) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1 | 3.01 ± 0.768 | 3.08 ± 0.797 |
| FVC | -3.96 ± 0.965 | 4.04 ± 1.031 |
Percent change in FEV1 and FVC from baseline (%) were reported. FEV1: the maximal volume of air exhaled from the lungs in 1 second of a forced expiration from a position of full inspiration as measured by spirometer. FVC: the volume of air (in liters) that can be forcibly blown out after full inspiration in the upright position. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. In this outcome measure, results were presented for extension end of treatment visit.
| Percent change | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1 | -7.96 ± 13.356 | -6.75 ± 12.323 |
| FVC | -5.09 ± 11.793 | -3.93 ± 12.141 |
Number of participants with treatment-emergent SAEs were reported. A SAE was defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to a congenital anomaly/birth defect in the offspring of a participant, or was an important medical event. Treatment-emergent SAEs are defined as SAEs occurring from start of treatment up to treatment end date + 15 days.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) | 56 (0.442 to —) | 57 (0.380 to —) |
Number of participants with treatment-emergent AESIs were reported. AESIs included bradyarrhythmia occurred post-first dose, macular edema, bronchoconstriction, severe liver injury, serious opportunistic infections including progressive multifocal leukoencephalopathy (PML), skin cancer, non-skin malignancy, convulsions, unexpected neurological or psychiatric symptoms/signs (posterior reversible encephalopathy syndrome \[PRES\], acute disseminated encephalomyelitis \[ADEM\], and atypical MS relapses). Treatment-emergent AESIs are defined as AESIs occurring from start of treatment up to treatment end date + 15 days.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Bradyarrhythmia occurring post-first dose | 11 | 13 |
| Severe liver injury | 5 | 5 |
| Bronchoconstriction | 31 | 25 |
| Macular edema | 4 | 6 |
| Serious opportunistic infections including PML | 2 | 1 |
| Skin cancer | 4 | 3 |
| Non-skin malignancy | 4 | 3 |
| Unexpected neurological or psychiatric symptoms / signs (PRES, ADEM, atypical MS relapses) | 1 | 2 |
| Convulsions | 2 | 3 |
Number of participants with AE leading to premature discontinuation of study treatment were reported. An AE is any untoward medical event that occurs in a participant being administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as AEs occurring from start of treatment up to treatment end date + 15 days.
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Number of Participants With AE Leading to Premature Discontinuation of Study Treatment | 34 | 41 |
Number of participants with treatment-emergent decrease from baseline \>20% and \>30% in FEV1 or FVC were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1: >20 % | 80 | 82 |
| FEV1: >30 % | 18 | 21 |
| FVC: >20 % | 54 | 60 |
| FVC: >30 % | 19 | 15 |
Number of participants with treatment-emergent decrease of \>20% points in percent predicted FEV1 and FVC from baseline were reported. Treatment-emergent is defined as events occurring from start of treatment up to treatment end date + 15 days (that is, findings not present at any assessment prior to first treatment in the extension study).
| Participants | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1: >20 % | 70 | 68 |
| FVC: >20 % | 59 | 57 |
Number of participants with a decrease of \>=200 mL or \>=12% in FEV1 or FVC from baseline to EOT were planned to be reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study. This endpoint is not relevant as a substantial proportion of patients continued onto post-treatment disease-modifying therapy (DMT), hence it cannot provide an assessment of reversibility.
No measurements were reported for this outcome.
Change in FEV1 and FVC (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
| Percentage predicted change | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1 | -7.14 ± 13.315 | -5.43 ± 11.839 |
| FVC | -4.70 ± 13.129 | -3.19 ± 13.081 |
Change in FEV1 and FVC (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
| Percentage predicted change | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| FEV1 | -5.95 ± 12.854 | -4.08 ± 14.365 |
| FVC | -4.48 ± 13.727 | -1.98 ± 15.747 |
Absolute change in lung diffusion capacity as assessed by DL\[CO\] from baseline were reported. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
| Millimoles/minute/kilopascal | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Absolute Change in Lung Diffusion Capacity as Assessed by Diffusing Capacity for the Lungs Measured Using Carbon Monoxide (DL[CO]) From Baseline | 0.7 ± 3.44 | 0.1 ± 4.17 |
Change in DL\[CO\] (% predicted) from baseline to EOT were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
| Percentage predicted DL[CO] | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Change in DL[CO] (% Predicted) From Baseline to EOT | 5.7 ± 32.20 | -9.4 ± 7.82 |
Change in DL\[CO\] (% predicted) from baseline to EOS were predicted. Extension baseline for safety is the last valid non-missing assessment that is taken on or after EOT visit in the core study, and prior to first study drug intake in the extension study.
| Percentage predicted DL[CO] | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Change in DL[CO] (% Predicted) From Baseline to EOS | 9.3 ± 39.38 | 2.2 ± 49.50 |
Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: heart rate were reported.
| beats per minute (bpm) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Predose | 68.1 ± 8.73 | 71.0 ± 9.21 |
| 1 hour Post-dose | 66.5 ± 10.53 | 69.0 ± 10.13 |
| 2 hours Post-dose | 64.3 ± 9.91 | 65.1 ± 8.68 |
| 3 hours Post-dose | 64.6 ± 9.33 | 67.8 ± 10.71 |
| 4 hours Post-dose | 66.0 ± 9.73 | 67.6 ± 10.01 |
Actual values of 12-lead ECG measurements on day of first Re-initiation (Day 1) of study drug: PR, QRS, QT, QTcB, QTcF were reported.
| millisecond (ms) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| PR Interval: Predose | 152.8 ± 17.66 | 149.8 ± 19.13 |
| PR Interval: 1 hour Post-dose | 150.5 ± 17.25 | 152.6 ± 22.66 |
| PR Interval: 2 hours Post-dose | 150.1 ± 16.60 | 153.6 ± 23.51 |
| PR Interval: 3 hours Post-dose | 152.3 ± 17.73 | 154.5 ± 21.91 |
| PR Interval: 4 hours Post-dose | 150.7 ± 17.82 | 151.8 ± 19.68 |
| QRS Duration: Predose | 94.6 ± 11.06 | 91.5 ± 7.03 |
| QRS Duration: 1 hour Post-dose | 95.2 ± 11.42 | 93.2 ± 8.72 |
| QRS Duration: 2 hours Post-dose | 93.9 ± 11.71 | 92.7 ± 7.57 |
| QRS Duration: 3 hours Post-dose | 94.5 ± 11.60 | 94.5 ± 7.80 |
| QRS Duration: 4 hours Post-dose | 94.7 ± 10.48 | 92.5 ± 7.35 |
| QT Interval: Predose | 391.5 ± 24.80 | 378.8 ± 23.61 |
| QT Interval: 1 hour Post-dose | 396.7 ± 28.76 | 380.9 ± 21.78 |
| QT Interval: 2 hours Post-dose | 402.0 ± 29.00 | 386.0 ± 19.62 |
| QT Interval: 3 hours Post-dose | 400.2 ± 27.78 | 386.9 ± 21.38 |
| QT Interval: 4 hours Post-dose | 400.0 ± 27.49 | 383.9 ± 23.14 |
| QTcB Interval: Predose | 416.2 ± 19.05 | 411.4 ± 20.85 |
| QTcB Interval: 1 hour Post-dose | 416.0 ± 24.11 | 407.6 ± 22.96 |
| QTcB Interval: 2 hours Post-dose | 414.8 ± 22.83 | 401.7 ± 20.88 |
| QTcB Interval: 3 hours Post-dose | 414.2 ± 23.30 | 410.1 ± 22.33 |
| QTcB Interval: 4 hours Post-dose | 418.0 ± 20.30 | 406.6 ± 22.33 |
| QTcF Interval: Predose | 407.4 ± 17.09 | 400.0 ± 18.69 |
| QTcF Interval: 1 hour Post-dose | 409.2 ± 20.58 | 398.1 ± 18.22 |
| QTcF Interval: 2 hours Post-dose | 410.1 ± 20.41 | 396.2 ± 16.61 |
| QTcF Interval: 3 hours Post-dose | 409.0 ± 20.97 | 402.0 ± 16.82 |
| QTcF Interval: 4 hours Post-dose | 411.5 ± 18.36 | 398.5 ± 18.27 |
Collected over Serious and Other AEs:From treatment start in extension study to EOT+15 days in extension study. Actual time varied till 71.8 months+15 days; All-cause mortality:From extension study baseline to EOS in extension study. Actual time varied till 73.2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ponesimod 20 mg (Core and Extension Study) | 1/439 (0.2%) | 56/439 (12.8%) | 339/439 (77.2%) |
| Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | 0/438 (0%) | 57/438 (13%) | 328/438 (74.9%) |
| Event | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| AppendicitisInfections and infestations | 3/439 | 3/438 |
| Acute Myocardial InfarctionCardiac disorders | 0/439 | 2/438 |
| Umbilical HerniaGastrointestinal disorders | 0/439 | 2/438 |
| CholelithiasisHepatobiliary disorders | 0/439 | 2/438 |
| Covid-19 PneumoniaInfections and infestations | 1/439 | 2/438 |
| PneumoniaInfections and infestations | 0/439 | 2/438 |
| Upper Limb FractureInjury, poisoning and procedural complications | 0/439 | 2/438 |
| Spinal PainMusculoskeletal and connective tissue disorders | 0/439 | 2/438 |
| Multiple Sclerosis RelapseNervous system disorders | 1/439 | 2/438 |
| Complicated AppendicitisInfections and infestations | 2/439 | 0/438 |
| Event | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) |
|---|---|---|
| Covid-19Infections and infestations | 115/439 | 108/438 |
| Alanine Aminotransferase IncreasedInvestigations | 73/439 | 98/438 |
| NasopharyngitisInfections and infestations | 82/439 | 74/438 |
| LymphopeniaBlood and lymphatic system disorders | 66/439 | 64/438 |
| HeadacheNervous system disorders | 57/439 | 64/438 |
| Upper Respiratory Tract InfectionInfections and infestations | 47/439 | 51/438 |
| Back PainMusculoskeletal and connective tissue disorders | 45/439 | 30/438 |
| HypertensionVascular disorders | 37/439 | 44/438 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 31/439 | 38/438 |
| Urinary Tract InfectionInfections and infestations | 36/439 | 33/438 |
The extension set included all participants who signed an informed consent to enter the extension study and who received at least one dose of ponesimod study medication in the extension study.
| Age, Categorical(Participants) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 439 | 438 | 877 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | Total |
|---|---|---|---|
| Mean | 36.5 ± 8.75 | 37.2 ± 8.75 | 36.8 ± 8.75 |
| Sex: Female, Male(Participants) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | Total |
|---|---|---|---|
| Female | 286 | 290 | 576 |
| Male | 153 | 148 | 301 |
| Ethnicity (NIH/OMB)(Participants) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 17 | 39 |
| Not Hispanic or Latino | 409 | 411 | 820 |
| Unknown or Not Reported | 8 | 10 | 18 |
| Race (NIH/OMB)(Participants) | Ponesimod 20 mg (Core and Extension Study) | Teriflunomide 14 mg (Core) Then Ponesimod 20 mg (Extension) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 2 | 4 |
| White | 429 | 430 | 859 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 6 | 14 |
Showing the first 100 of 148 sites across 28 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Jan 2024, 78 months.
Results were first posted in Feb 2025, 1 year 1 month after primary completion.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 78 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ponesimod